• Je něco špatně v tomto záznamu ?

Growth Differentiation Factor-15 Is Associated With Congestion-Related Anorexia and Weight Loss in Advanced Heart Failure

L. Monzo, P. Jarolim, BA. Borlaug, J. Benes, I. Jurcova, D. Jenca, K. Kroupova, P. Wohlfahrt, M. Kotrc, V. Melenovsky

. 2025 ; 13 (2) : 315-329. [pub] 20250108

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010036

BACKGROUND: Growth differentiation factor (GDF)-15 is a pleiotropic cytokine that is associated with appetite-suppressing effects and weight loss in patients with malignancy. OBJECTIVES: This study aims to investigate the relationships between GDF-15 levels, anorexia, cachexia, and clinical outcomes in patients with advanced heart failure with reduced ejection fraction (HFrEF). METHODS: In this observational, retrospective analysis, a total of 344 patients with advanced HFrEF (age 58 ± 10 years, 85% male, 67% NYHA functional class III), underwent clinical and echocardiographic examination, body composition evaluation by skinfolds and dual-energy x-ray absorptiometry, circulating metabolite assessment, Minnesota Living with Heart Failure Questionnaire, and right heart catheterization. RESULTS: The median GDF-15 level was 1,503 ng/L (Q1-Q3: 955-2,332 ng/L) (reference range: <1,200 ng/L). Higher GDF-15 levels were associated with more prevalent anorexia and cachexia. Patients with higher GDF-15 had increased circulating free fatty acids and beta-hydroxybutyrate, lower albumin, cholesterol, and insulin/glucagon ratio, consistent with a catabolic state. Patients with higher GDF-15 had worse congestion and more severe right ventricular dysfunction. In multivariable Cox analysis, elevated GDF-15 was independently associated with risk of the combined endpoint of death, urgent transplantation, or left ventricular assist device implantation, even after adjusting for coexisting anorexia and cachexia (T3 vs T1 HR: 2.31 [95% CI: 1.47-3.66]; P < 0.001). CONCLUSIONS: In patients with advanced HFrEF, elevated circulating GDF-15 levels are associated with a higher prevalence of anorexia and cachexia, right ventricular dysfunction, and congestion, as well as an independently increased risk of adverse events. Further studies are warranted to determine whether therapies altering GDF-15 signaling pathways can affect metabolic status and clinical outcomes in advanced HFrEF.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010036
003      
CZ-PrNML
005      
20250429135349.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jchf.2024.10.023 $2 doi
035    __
$a (PubMed)39797849
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Monzo, Luca $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic; Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France
245    10
$a Growth Differentiation Factor-15 Is Associated With Congestion-Related Anorexia and Weight Loss in Advanced Heart Failure / $c L. Monzo, P. Jarolim, BA. Borlaug, J. Benes, I. Jurcova, D. Jenca, K. Kroupova, P. Wohlfahrt, M. Kotrc, V. Melenovsky
520    9_
$a BACKGROUND: Growth differentiation factor (GDF)-15 is a pleiotropic cytokine that is associated with appetite-suppressing effects and weight loss in patients with malignancy. OBJECTIVES: This study aims to investigate the relationships between GDF-15 levels, anorexia, cachexia, and clinical outcomes in patients with advanced heart failure with reduced ejection fraction (HFrEF). METHODS: In this observational, retrospective analysis, a total of 344 patients with advanced HFrEF (age 58 ± 10 years, 85% male, 67% NYHA functional class III), underwent clinical and echocardiographic examination, body composition evaluation by skinfolds and dual-energy x-ray absorptiometry, circulating metabolite assessment, Minnesota Living with Heart Failure Questionnaire, and right heart catheterization. RESULTS: The median GDF-15 level was 1,503 ng/L (Q1-Q3: 955-2,332 ng/L) (reference range: <1,200 ng/L). Higher GDF-15 levels were associated with more prevalent anorexia and cachexia. Patients with higher GDF-15 had increased circulating free fatty acids and beta-hydroxybutyrate, lower albumin, cholesterol, and insulin/glucagon ratio, consistent with a catabolic state. Patients with higher GDF-15 had worse congestion and more severe right ventricular dysfunction. In multivariable Cox analysis, elevated GDF-15 was independently associated with risk of the combined endpoint of death, urgent transplantation, or left ventricular assist device implantation, even after adjusting for coexisting anorexia and cachexia (T3 vs T1 HR: 2.31 [95% CI: 1.47-3.66]; P < 0.001). CONCLUSIONS: In patients with advanced HFrEF, elevated circulating GDF-15 levels are associated with a higher prevalence of anorexia and cachexia, right ventricular dysfunction, and congestion, as well as an independently increased risk of adverse events. Further studies are warranted to determine whether therapies altering GDF-15 signaling pathways can affect metabolic status and clinical outcomes in advanced HFrEF.
650    _2
$a lidé $7 D006801
650    12
$a růstový diferenciační faktor 15 $x krev $7 D055436
650    _2
$a mužské pohlaví $7 D008297
650    12
$a srdeční selhání $x komplikace $x patofyziologie $x krev $7 D006333
650    _2
$a lidé středního věku $7 D008875
650    _2
$a ženské pohlaví $7 D005260
650    12
$a hmotnostní úbytek $7 D015431
650    _2
$a retrospektivní studie $7 D012189
650    12
$a nechutenství $x etiologie $7 D000855
650    12
$a kachexie $x etiologie $7 D002100
650    _2
$a tepový objem $x fyziologie $7 D013318
650    _2
$a senioři $7 D000368
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Jarolim, Petr $u Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Department of Pathology, Boston, Massachusetts, USA
700    1_
$a Borlaug, Barry A $u Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a Benes, Jan $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Jurcova, Ivana $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Jenca, Dominik $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Kroupova, Katerina $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Wohlfahrt, Peter $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Kotrc, Martin $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Melenovsky, Vojtech $u Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic. Electronic address: vome@ikem.cz
773    0_
$w MED00184931 $t JACC. Heart failure $x 2213-1787 $g Roč. 13, č. 2 (2025), s. 315-329
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39797849 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135344 $b ABA008
999    __
$a ok $b bmc $g 2311417 $s 1247117
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 13 $c 2 $d 315-329 $e 20250108 $i 2213-1787 $m JACC. Heart failure $n JACC Heart Fail $x MED00184931
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...